Interferon and immunoglobulin fc fragment hybrid

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 38/21 (2006.01) A61K 39/00 (2006.01) A61K 39/395 (2006.01) C07K 1/00 (2006.01) C07K 16/00 (2006.01)

Patent

CA 2495480

The present invention provides interferon-immunoglobulin Fc fusion proteins ("IFN-Fc hybrids") that are useful for removing or regressing tumors or delaying tumor development. The IFN-Fc hybrids preferably include peptide linkers between the IFN and the Fc fragment. These linkers are T cell inert sequences or any non-immunogenic sequence, preferably Gly-Ser repeat units. The preferred Fc fragment is a human immunoglobulin Fc fragment, preferably the .gamma.4 chain.

L'invention concerne des protéines de fusion interféron-immunoglobuline Fc (<= hybrides IFN-Fc >=) qui sont utiles pour enlever ou faire régresser des tumeurs ou pour retarder leur évolution. Ces hybrides comprennent de préférence des peptides de liaison entre l'IFN et le fragment Fc. Ces lieurs sont des séquences inertes de lymphocytes T ou une séquence non-immunogène quelconque, de préférence des unités de répétition Gly-Ser. Le fragment Fc préféré est un fragment Fc d'immunoglobuline humain, de préférence la chaîne .gamma.4.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Interferon and immunoglobulin fc fragment hybrid does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Interferon and immunoglobulin fc fragment hybrid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interferon and immunoglobulin fc fragment hybrid will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2051319

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.